Clinical Trial Update: An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating safety and efficacy of subcutaneous recombinant interferon-gamma 1b in patients with idiopathic pulmonary fibrosis; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Interferon gamma-1b (Actimmune) (Interferon gamma-1b)

Snippet

Sponsor: InterMune | Conditions: Lung Disease, Pulmonary Fibrosis | Phase 2 | Status: COMPLETED